Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,620 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis.
Adams D, Gonzalez-Duarte A, O'Riordan WD, Yang CC, Ueda M, Kristen AV, Tournev I, Schmidt HH, Coelho T, Berk JL, Lin KP, Vita G, Attarian S, Planté-Bordeneuve V, Mezei MM, Campistol JM, Buades J, Brannagan TH 3rd, Kim BJ, Oh J, Parman Y, Sekijima Y, Hawkins PN, Solomon SD, Polydefkis M, Dyck PJ, Gandhi PJ, Goyal S, Chen J, Strahs AL, Nochur SV, Sweetser MT, Garg PP, Vaishnaw AK, Gollob JA, Suhr OB. Adams D, et al. Among authors: ueda m. N Engl J Med. 2018 Jul 5;379(1):11-21. doi: 10.1056/NEJMoa1716153. N Engl J Med. 2018. PMID: 29972753 Free article. Clinical Trial.
Impact of antibodies against amyloidogenic transthyretin (ATTR) on phenotypes of patients with familial amyloidotic polyneuropathy (FAP) ATTR Valine30Methionine.
Obayashi K, Tasaki M, Jono H, Ueda M, Shinriki S, Misumi Y, Yamashita T, Oshima T, Nakamura T, Ikemizu S, Anan I, Suhr O, Ando Y. Obayashi K, et al. Among authors: ueda m. Clin Chim Acta. 2013 Apr 18;419:127-31. doi: 10.1016/j.cca.2013.02.002. Epub 2013 Feb 24. Clin Chim Acta. 2013. PMID: 23462670
Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR-FAP) with Val30Met and non-Val30Met: A phase III, open-label study.
Ando Y, Sekijima Y, Obayashi K, Yamashita T, Ueda M, Misumi Y, Morita H, Machii K, Ohta M, Takata A, Ikeda S. Ando Y, et al. Among authors: ueda m. J Neurol Sci. 2016 Mar 15;362:266-71. doi: 10.1016/j.jns.2016.01.046. Epub 2016 Jan 22. J Neurol Sci. 2016. PMID: 26944161 Clinical Trial.
Novel Antibody for the Treatment of Transthyretin Amyloidosis.
Hosoi A, Su Y, Torikai M, Jono H, Ishikawa D, Soejima K, Higuchi H, Guo J, Ueda M, Suenaga G, Motokawa H, Ikeda T, Senju S, Nakashima T, Ando Y. Hosoi A, et al. Among authors: ueda m. J Biol Chem. 2016 Nov 25;291(48):25096-25105. doi: 10.1074/jbc.M116.738138. Epub 2016 Oct 7. J Biol Chem. 2016. PMID: 27758856 Free PMC article.
4,620 results